Amid shortages of cancer drugs in the U.S., the API Innovation Center will use continuous manufacturing technology and a partnership with Apertus Pharmaceuticals and the Glioblastoma Foundation to ...

Industry groups have identified upfront costs as a barrier to streamlining U.S. drugmaking. The nonprofit API Innovation Center has a proposed answer for how to tilt finances in favor of investments ...

Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.

BioDuro, a CRDMO, has established a joint venture with Cenra API Solutions, a pharmaceutical chemical manufacturer in Taiwan.

As the pharmaceutical industry continues to evolve in the wake of pandemic-driven disruptions and heightened regulatory scrutiny, the role of the top pharmaceutical API manufacturer has taken on ...

Technological innovations throughout the past several decades have transformed the pharmaceutical manufacturing process from traditional batch production to ...